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 Introduction 
 Hepatitis E is caused by hepatitis E virus (HEV) that is 
generally manifested by a self-limiting acute infection, and 
in some cases, by fulminant liver disease  [1] . HEV is a non-
enveloped virus, the only member of the Hepeviridae fam-
ily, and contains a positive-sense, single-stranded RNA 
genome of  ∼ 7.2 kb  [2] . Of the three open reading frames, 
ORF1 encodes a nonstructural polyprotein essential for 
viral RNA replication, and ORF2 codes for the viral capsid 
protein. ORF3 translates into a very small protein, attrib-
uted to some regulatory functions, including establishing 
viral infection to the host  [3, 4] . However, HEV biology 
has so far not been completely understood, due to the lack 
of a robust in vivo or in vitro  experimental model of infec-
tion. The viral infection may be symptomatic or asymp-
tomatic with an overall fatality rate of about 2% worldwide 
 [5] . In developing countries, it is primarily transmitted 
through contaminated water due to poor sanitation and is 
often associated with large epidemics  [1, 5] . In endemic 
regions, cases of mortalities due to fulminant liver failure 
may also occur in about 20–30% of pregnant women or in 
persons with pre-existing chronic liver disease  [1] . In con-
trast, in industrialized nations, like Japan, USA, Canada 
and many European countries, HEV infection occurs spo-
radically. The absence of travel to endemic areas and the 
isolation of genetically different HEV strains have sup-
ported an autochthonous origin of such sporadic cases in 
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 Abstract 
 Very recently, an unusual clinical presentation with an al-
tered natural history associated with hepatitis E virus (HEV) 
infection has emerged in high-income industrialized na-
tions. Although HEV infection does not develop into chro-
nicity in general, viremia can persist for long periods of time 
in immunocompromised solid organ, bone marrow and 
stem cell transplant patients. Conceivably, the atypical clin-
ical and virological outcomes in these cases could be relat-
ed to immunosuppressive chemotherapy, resulting in sub-
optimal HEV-specific immune responses. In the absence of 
travel to endemic regions, foodborne autochthonous HEV 
infection due to viral genotypes 3 and 4 has been implicat-
ed in the chronic cases. Presently, pegIFN-α-2a and ribavirin, 
the commonly used drugs to treat chronic viral hepatitis, 
are proving very promising in hepatitis E patients. Neverthe-
less, the most-awaited HEV vaccine could be protective in 
naïve travelers or high-risk group populations. The mecha-
nisms of establishing chronic HEV infection and the disease 
severity have hitherto not been clearly understood.  There-
fore,  a comprehensive clinical, virological and molecular 
study is needed to understand and control the disease. 
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North America and Europe  [6] . Nevertheless, the sources 
and routes of indigenous HEV infections in the developed 
countries are still uncertain and not clearly defined.
 Chronic HEV Infection 
 Among the human hepatitis viruses (A, B, C, D and E), 
only HBV, HCV and HDV are well known to cause chro-
nic liver diseases. HEV infection is generally acute  [7–9] 
( table 1 ), and in most of the cases it is spontaneously clear-
ed and, therefore, remains clinically silent. Acute viral hep-
atitis is manifested by typical symptoms, such as vomiting, 
myalgia, weakness, jaundice, uncolored stool and dark-
ened urine. Serological markers of the illness include in-
creased levels of liver transaminases, bilirubin, alkaline 
phosphatases and γ-glutamyltransferase, and in the HEV 
infection, detection of anti-HEV IgG/IgM antibodies as 
well as HEV-RNA in serum and stool. On the other hand, 
in the chronic course of hepatitis virus infection, there is a 
persistent increase in levels of liver enzymes, significant 
histopathological activity, including viral markers and 
 nucleic acids. In recent years, unusual clinical presenta-
tions with severe outcomes have been encountered in as-
sociation with autochthonous HEV chronic infections in 
North America and Europe. Recently, several cases of per-
sistent HEV infection associated with progressive liver 
 disease have been reported in Dutch  [10, 11] , German  [12, 
13] , French  [14] and Canadian  [15] immunosuppressed 
solid organ transplant patients ( table 2 ). Moreover, cases 
of viral reactivation after stem cell transplantation in leu-
kemia patients were also reported 3 years ago  [16] . All 
these confirmed chronic hepatitis E cases showed persis-
tent elevations in liver enzymes, anti-HEV IgG and HEV-
RNA in patients’ serum as well as viral RNA in stool sam-
ples after a mean period of >12 months. So far, HEV-relat-
ed liver cirrhosis has not been established but the 
development of cirrhosis in liver  [17] and bone marrow 
 [18] transplant recipients has been observed, too. Very re-
cently, Kamar et al.  [19]  described about 66% chronic cas-
es in HEV-infected solid organ transplant recipients and 
found a significant reduction in CD2+, CD3+ and CD4+ 
T lymphocyte counts in chronic hepatitis E patients as well 
as in those at risk of developing fulminant liver failure. In 
another study of HIV-positive Swiss patients with very low 
CD4+ T cell count, persistent HEV-RNA (>24 months) 
was detected with a delayed seroconversion  [20] .
 Chemotherapy with immunosuppressive drugs, such as 
tacrolimus (FK-506 or fujimycin), is considered as the main 
predictive factor for the development of chronicity in HEV-
infected individuals  [21] . It is thus, conceivable that the 
atypical natural history and outcomes of chronic hepatitis 
E could be related to immunosuppression, which might 
have resulted in suboptimal HEV-specific host immune re-
sponses, favoring viral persistence. Moreover, HIV-coin-
fected patients with an advanced stage of immunodeficien-
cy represent another population at risk of HEV-associated 
chronic liver diseases  [20, 22] . To sum up, impaired adap-
tive immune responses may be a potential reason in Euro-
pean cases for the establishment of chronic HEV infection. 
Nevertheless, the molecular mechanisms of persistent HEV 
infection and the disease severity in immunocompromised 
individuals have hitherto not been clearly understood.
 Risk Factors and Transmission Routes 
 Human HEV has four recognized genotypes, namely 1, 
2, 3 and 4, all representing a single serotype  [23] . Genotypes 
1 and 2 infect only humans and primates, and have no 
known animal reservoir. While genotype 1 is prevalent in 
Asia, including the Middle East, genotype 2 is distributed 
in African and Latin American countries  [1] . In contrast, 
genotypes 3 and 4 are zoonotic and primarily infect pigs 
Table 1.  Cases of autochthonous acute HEV infection
Genotype Zoonosis Country Ref. 
No.
Kidney transplant
Liver transplant
XIAP immunodeficiency
Lymphoblastic leukemia
Myeloblastic leukemia
3
3
3
3
4
porcine
porcine
porcine
porcine
porcine
France
France
France
France
France
[7]
[8]
[8]
[8]
[9]
Table 2.  Cases of chronic hepatitis E in immunocompromised 
groups
Geno-
type
Zoonosis Country Ref. 
No.
Liver transplant 3 porcine The Netherlands
Germany
France
Canada
[10, 11]
[12]
[14]
[15]
Kidney transplant 
Stem cell transplant
Bone marrow
transplant
HIV coinfection
3
3
3
3
porcine
porcine
porcine
porcine
Germany
Germany
Canada
Switzerland
[13]
[16]
[18]
[19]
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and some other mammals, in addition to humans  [1] . Gen-
otype 3 and 4 are mainly limited to Eastern Asian countries, 
Eastern and Western Europe and North America  [1, 9, 23] . 
Although less pathogenic than genotypes 1 and 2, geno-
types 3 and 4 have been implicated in the European locally 
acquired hepatitis E sporadic cases  [9, 24] . Of note, human 
and swine HEV are genetically very close with approxi-
mately 99% sequence homology, in cases where direct zoo-
notic transmission is assumed  [25, 26] . Swine HEV was first 
isolated and genetically characterized from farm pigs in the 
USA  [27] , followed by reports on many porcine isolates 
from some Asian and European countries. Subsequently, 
several descriptive studies on HEV prevalence had been 
carried out in cases with swine contact, including pig feces 
or slurry, and commercially sold liver in Japan, the USA, 
Canada, New Zealand, the Netherlands, Spain and the UK 
 [28] . Since pigs represent a large reservoir of HEV in non-
endemic regions, they are considered as a potential source 
of infection. Recently, a direct viral transmission through 
the consumption of contaminated pork in Japan as well as 
a link between eating raw pork liver sausage and the au-
tochthonous HEV chronic infection in France has been re-
ported  [28] . Moreover, strains of HEV have been geneti-
cally detected in wild boars, deers, mongooses, rabbits and 
rats in different parts of the world, including Europe and 
the USA  [28] . Several studies conducted in Europe have 
supported a foodborne origin of indigenous HEV (geno-
type 3) infection due to the consumption of gourmet fi-
gatellu and offal, including game meat of wild boar  [29–32] . 
Fortunately, neither is genotype 1 and 2 infection in asso-
ciation with chronic progression reported elsewhere nor 
are there any data available on HEV chronic cases in im-
munocompetent individuals. Also, there is no information 
on the isolation of specific viral mutations or genetic vari-
ants related to this chronic adaptation in the immunosup-
pressed individuals. Interestingly, a very recent study of 
genotype 3 isolate from a chronic patient has revealed a 
recombinant viral-host genome that was infectious to 
swine, deer and human hepatocytes in vitro  [33] . This find-
ing strongly supports a cross-species adaptation of zoono-
tic HEV strains and their pathogenicity in humans.
 Prevention and Control 
 The proper and timely diagnosis of HEV infection is 
technically challenging. The lack of an approved algo-
rithm, the consistency of serological tests and viral load 
quantification in terms of sensitivity and specificity are the 
limiting factors. Furthermore, serology alone may be in-
sufficient to diagnose HEV coinfection in HIV-positive 
patients because of delayed or failed seroconversion. 
Needless to say, there has been no established treatment 
for acute HEV infection and the resulting disease as far as 
its natural history is concerned. In the current situation, 
pegylated IFN-α-2a has been successfully used for treating 
chronic hepatitis E in transplant recipients  [34] . Further, 
ribavirin is also shown to inhibit the viral RNA replication 
and induce a sustained virological response in chronically 
infected patients  [35] . The safety and efficacy of an HEV 
vaccine have already been evaluated in a phase II clinical 
trial, showing a very good efficacy of up to 95.5%  [36] . 
HEV infection can, therefore, be controlled with an effi-
cient immunization program where individuals in endem-
ic areas as well as naïve travelers from nonendemic regions 
could also be protected. In industrialized countries, popu-
lations at risks such as transplant recipients or people with 
underlying liver conditions could be vaccinated as well. In 
a public health care initiative, the French health authority 
published in its 2009 recommendations that pork liver 
sausages should be cooked prior to consumption. Precau-
tions and proper care should, therefore, be taken when 
selecting, purchasing or hunting high-risk animals and 
cooking their meat. Furthermore, those employed as farm-
ers, pig herders or veterinarians and who work with reser-
voir or high-risk animals as well as sewage workers must 
take precautionary measures to ensure adequate hygiene. 
Last but not the least, HEV infection-associated quantita-
tive risk assessments would further allow to identify pos-
sible and potential transmission routes and to precisely 
define the strategy of viral surveillance and control.
 Conclusion 
 The recent trend of chronic HEV infection, at least in the 
immunocompromised individuals, certainly makes HEV 
very important, in line with other hepatitis viruses such as 
HBV and HCV. A further comprehensive clinical, virolog-
ical and molecular study is needed to understand and con-
trol this viral paradigm shift and the disease severity.
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